Legence Corp. Files S-1 Registration Statement

TL;DR

Legence Corp. just filed its S-1, looks like they're going public soon.

AI Summary

Legence Corp. filed an S-1 registration statement with the SEC on April 6, 2026. The filing details the company's intention to register securities, though specific dollar amounts or the number of shares are not yet disclosed in this initial filing. The company is located at 1601 Las Plumas Avenue, San Jose, CA 95133.

Why It Matters

This S-1 filing is the first step for Legence Corp. to potentially offer its securities to the public, indicating a move towards becoming a publicly traded company.

Risk Assessment

Risk Level: medium — An S-1 filing is a preliminary step and does not guarantee a successful public offering or provide full financial details, making the risk level medium until more information is available.

Key Players & Entities

• Legence Corp. (company) — Filer of the S-1 registration statement
• 0002052568 (company) — CIK number for Legence Corp.
• 2026-04-06 (date) — Filing date of the S-1
• 1601 LAS PLUMAS AVENUE SAN JOSE CA 95133 (company) — Mailing and Business Address for Legence Corp.

FAQ

Key Financial Figures

• $0.01 — ares of Class A common stock, par value $0.01 per share ("Class A Common Stock"), to
• $58.68 — Class A Common Stock on the Nasdaq was $58.68 per share. Investing in our Class A C
• $3.7 billion — arkets. As of December 31, 2025, we had $3.7 billion of backlog and awarded contracts, repre
• $10 m — s that had contract prices of less than $10 million, after giving pro forma effect to
• $436.3 million — y, we paid subcontractors approximately $436.3 million and $350.7 million, respectively, in co
• $350.7 m — actors approximately $436.3 million and $350.7 million, respectively, in connection with
• $592.1 million — , 2025 and 2024, we spent approximately $592.1 million and $457.3 million, respectively, on eq
• $457.3 m — spent approximately $592.1 million and $457.3 million, respectively, on equipment for o
• $2,550.5 million — r ended December 31, 2025, we generated $2,550.5 million in revenue, $77.3 million in net loss a
• $77.3 million — generated $2,550.5 million in revenue, $77.3 million in net loss and $298.8 million in Adjus
• $298.8 million — revenue, $77.3 million in net loss and $298.8 million in Adjusted EBITDA representing a Net L
• $279 billion — uildings in the United States grew from $279 billion in 2021 to $437 billion in 2024, repres
• $437 billion — tates grew from $279 billion in 2021 to $437 billion in 2024, representing a compound annual
• $7 billion — es investment in data centers grew from $7 billion in 2021 to an estimated $48 billion in
• $48 billion — from $7 billion in 2021 to an estimated $48 billion in 2025 and is forecast to grow to $70

Filing Documents

• d43269ds1.htm (S-1) — 1222KB
• d43269dex11.htm (EX-1.1) — 223KB
• d43269dex51.htm (EX-5.1) — 12KB
• d43269dex232.htm (EX-23.2) — 2KB
• d43269dex233.htm (EX-23.3) — 2KB
• d43269dexfilingfees.htm (EX-FILING FEES) — 17KB
• g43269g00a03.jpg (GRAPHIC) — 38KB
• g43269g00z01.jpg (GRAPHIC) — 112KB
• g43269g94j11.jpg (GRAPHIC) — 3KB
• g43269g98c29.jpg (GRAPHIC) — 4KB
• 0001193125-26-142887.txt ( ) — 1779KB
• d43269dexfilingfees_htm.xml (XML) — 5KB

Risk Factors

Risk Factors 15 Cautionary Note Regarding Forward-Looking Statements 18

Use of Proceeds

Use of Proceeds 20 Principal and Selling Stockholders 21 Corporate Reorganization 24 Certain Relationships and Related Party Transactions 27 Dividend Policy 31

Description of Capital Stock

Description of Capital Stock 32 Material U.S. Federal Income Tax Considerations for Non-U.S. Holders 39 Underwriting (Conflicts of Interest) 44 Legal Matters 54 Experts 54 Where You Can Find More Information 55 Incorporation of Certain Information by Reference 56 Index to Financial Statements F-1 Neither we, nor the selling stockholders, nor the underwriters have authorized anyone to provide you with any information or to make any representations other than those contained or incorporated by reference in this prospectus, any amendment or supplement to this prospectus or any free writing prospectus prepared by us or on our behalf. We, the selling stockholders and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any information other than the information contained or incorporated by reference in this prospectus, any amendment or supplement to this prospectus or any free writing prospectus prepared by us or on our behalf. You should assume that the information appearing in this prospectus or any free writing prospectus is accurate only as of the date on its respective cover, and that any information incorporated by reference herein or therein is accurate only as of the date of the document incorporated by reference. Our business, financial condition, results of operations and prospects may have changed since such dates. We and the selling stockholders are not, and the underwriters are not, making an offer to sell these securities in any jurisdiction where an offer or sale is not permitted. This prospectus contains forward-looking statements that are subject to a number of risks and uncertainties, many of which are beyond our control. "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" contain additional information regarding these risks. i Table of Contents COMMONLY USED DEFINED TERMS As used in this prospectus, unless the context indicates or otherwise re

View Full Filing

View this S-1 filing on SEC EDGAR